Optimer Teams With AztraZeneca To Bring Dificid To South America
This article was originally published in PharmAsia News
Optimer has signed a string of partnerships to commercialize the antibiotic around the world; the latest is with AstraZeneca, which will market the drug in South America, Central America, Mexico and the Caribbean.
You may also be interested in...
Optimer expects the co-promotion to accelerate formulary adoption and uptake of the antibiotic at the 1,100 hospitals where 70% of hospital-related Clostridium dificile infections occur.
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.
Bayer pharmaceuticals executive Marianne De Backer will succeed Scangos at Vir, tasked with advancing several mid-stage programs in areas like hepatitis B and influenza to late-stage development.